Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Sep 2015)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment

  • Kristaps Klavins,
  • Therese Koal,
  • Guido Dallmann,
  • Josef Marksteiner,
  • Georg Kemmler,
  • Christian Humpel

DOI
https://doi.org/10.1016/j.dadm.2015.05.003
Journal volume & issue
Vol. 1, no. 3
pp. 295 – 302

Abstract

Read online

Abstract Background Metabolomic processes have been identified as being strongly linked to the development of Alzheimer's disease (AD). Thus, lipid metabolites appear to be highly useful as diagnostic substrates for the diagnosis of AD and mild cognitive impairment (MCI) in plasma. Methods We analyzed plasma samples from controls (n = 35), MCI (n = 33), and AD patients (n = 43) using the AbsoluteIDQ p180 Kit (Biocrates Life Sciences), which included quantitative analysis of 40 acylcarnitines, 21 amino acids, 19 biogenic amines, 15 sphingolipids, 90 glycerophospholipids, and sum of hexoses. Results We found that individual lipid metabolites can differentiate controls from MCI and AD with relevant significance. However, the ratio between PC aa C34:4 and lysoPC a C18:2 differentiates controls from MCI (P = .0000007) and from AD (P = .0000009) with greater significance. Conclusions The results provide evidence that the ratio of these two lipid metabolites is useful for diagnosing MCI and AD with an accuracy of 82%–85%.

Keywords